A deep dive into the intrinsic value of Aurelius Technologies Berhad (KLSE:ATECH) using a Discounted Cash Flow model suggests a potential disconnect between its market price and fundamental valuation, raising questions for investors.
As UPS announces a major workforce reduction linked to its Amazon partnership, investors are weighing the logistics giant's strategic pivot against its hefty 6% dividend yield. The move underscores a broader industry recalibration for profitability in a changing delivery landscape.
Fourth-quarter earnings for S&P 500 companies are significantly outperforming expectations, led by robust growth in industrial and tech sectors, as investors await a busy week of corporate results and key economic data.
Amid a brutal year for apparel stocks, Deckers Outdoor delivered a stunning earnings beat, sending shares soaring 19%. The performance of its HOKA and UGG brands, coupled with raised guidance, suggests Wall Street's pessimism may have been overblown for this long-term winner.
Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.
Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.
A broad crypto market sell-off has dragged AI-linked tokens to one of their steepest weekly declines in recent memory, erasing billions in value. Despite the price pain, key infrastructure projects in the decentralized AI and agent ecosystem continue to advance.
Australian miner ioneer has secured A$72 million in fresh capital to advance its flagship Nevada lithium-boron project. While the funds de-risk near-term construction, the discounted share placement sparks debate over strategic leverage versus shareholder dilution in a critical minerals race increasingly shaped by U.S. industrial policy.
A new cache of Jeffrey Epstein's emails has implicated former Prince Andrew, his ex-wife Sarah Ferguson, and senior Labour figure Peter Mandelson, revealing intimate correspondence, financial dealings, and raising fresh questions about influence and accountability at the highest levels of British society.
The parent company of Fatburger and Round Table Pizza, along with its Twin Hospitality spinoff, will be removed from the Nasdaq exchange effective February 4, transitioning to the over-the-counter market following Chapter 11 filings and over $1 billion in debt.
The Schwab U.S. Dividend Equity ETF (SCHD) offers investors a balanced approach to generating income, targeting financially robust companies with a history of growing dividends. We examine its strategy, performance, and role in a portfolio.
Despite a sharp sell-off in its shares, HubSpot reports a surge in new contract signings and projects an expanding free cash flow margin, signaling underlying operational strength even as investors remain wary.
As economic pressures mount, flexible remote work opportunities are evolving. We examine four proven side gigs that experts project can still generate significant weekly earnings from home in the coming years.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
The renewable energy firm's latest quarterly results, described as a 'beat and raise,' have prompted major banks to lift their valuations, signaling strong confidence in its growth trajectory within the clean energy sector.
Africa's used vehicle market is on track to expand at nearly 7% annually, approaching a $200 billion valuation by 2033, as demand for affordable personal transport surges across the continent.
Investment firm Curreen Capital posted a 30.97% annual return for 2025, crediting its focus on undervalued, well-managed companies. The firm's latest investor letter highlights home service provider Frontdoor (FTDR) as a key holding, despite it not being among the most popular hedge fund picks.
